Compare ADMA Biologics Inc (ADMA) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Halliburton Company — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Halliburton Company trades at $34.73 (market cap $28.23B). The key difference: Halliburton Company is far larger — about 13.3× ADMA Biologics Inc's market cap, and Halliburton Company pays a 2.01% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HAL | |
|---|---|---|
Market Cap | $2.13B | $28.23B |
Sector | Health | Energy |
52-Week High | $20.38 | $42.98 |
52-Week Low | $7.60 | $20.50 |
Enterprise Value | $2.20B | $34.31B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Halliburton (HAL) trades at $33.79, up 2.52% today, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 18.23 and ROE of 14.56%, though 2025 revenue declined to $22.18B. Recent news highlights digital transformation partnerships and upcoming Q2 2026 earnings, while analyst consensus remains strongly bullish with a $44.22 price target.
HAL presents a compelling value opportunity with 30% upside to consensus target, supported by consistent earnings outperformance and strategic digital initiatives. Key risks include oil price volatility and competitive pressures in energy services. The stock's current discount to analyst targets and strong institutional support suggest potential for recovery despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
